Elshazly Ahmed M, Wright Polina A, Xu Jingwen, Gewirtz David A
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Massey Cancer Center, 401 College St., Richmond, VA 23298, USA.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.
Autophagy Rep. 2023;2(1):1-16. doi: 10.1080/27694127.2022.2155904. Epub 2022 Dec 25.
Topoisomerase I inhibitors represent a widely used class of antineoplastic agents that promote both single-stranded and double-stranded breaks in the DNA of tumor cells, leading to tumor cell death. Topotecan and irinotecan are the clinically relevant derivatives of the parent drug, camptothecin. As is the case with many if not most anticancer agents, irinotecan and topotecan promote autophagy. However, whether the autophagy is cytotoxic, cytoprotective, or non-protective is not clearly defined, and may depend largely upon the genetic background of the tumor cell being investigated. This review explores the available literature regarding the nature of the autophagy induced by these clinically utilized topoisomerase I inhibitors in preclinical tumor models with the goal of determining whether the targeting of autophagy might have potential as a therapeutic strategy to enhance the antitumor response and/or overcome drug resistance.
拓扑异构酶I抑制剂是一类广泛使用的抗肿瘤药物,可促使肿瘤细胞DNA发生单链和双链断裂,从而导致肿瘤细胞死亡。拓扑替康和伊立替康是母体药物喜树碱的临床相关衍生物。与许多(即便不是大多数)抗癌药物一样,伊立替康和拓扑替康可促进自噬。然而,这种自噬是具有细胞毒性、细胞保护作用还是无保护作用尚不清楚,并且可能在很大程度上取决于所研究肿瘤细胞的基因背景。本综述探讨了关于这些临床应用的拓扑异构酶I抑制剂在临床前肿瘤模型中诱导自噬性质的现有文献,目的是确定靶向自噬是否有可能作为一种治疗策略来增强抗肿瘤反应和/或克服耐药性。